Global Anti-Venom Market Growth 2023-2029

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.

LPI (LP Information)' newest research report, the “Anti-Venom Industry Forecast” looks at past sales and reviews total world Anti-Venom sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-Venom sales for 2023 through 2029. With Anti-Venom sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Venom industry.

This Insight Report provides a comprehensive analysis of the global Anti-Venom landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Venom portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Anti-Venom market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Venom and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Venom.

The global Anti-Venom market size is projected to grow from US$ 938.3 million in 2022 to US$ 1264.8 million in 2029; it is expected to grow at a CAGR of 1264.8 from 2023 to 2029.

CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Venom market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:
Segmentation by type
    Polyvalent Anti-Venom
    Monovalent Anti-Venom

Segmentation by application
    Non-profit Institutions
    Hospitals and Clinic

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
    CSL
    Merck
    BTG
    Pfizer
    Haffkine Bio-Pharmaceutical
    Rare Disease Therapeutics
    Flynn Pharma
    Vins Bioproducts
    Bharat Serums and Vaccines
    Serum Biotech
    MicroPharm

Key Questions Addressed in this Report
What is the 10-year outlook for the global Anti-Venom market?
What factors are driving Anti-Venom market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-Venom market opportunities vary by end market size?
How does Anti-Venom break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

List of Tables
    Table 1. Anti-Venom Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
    Table 2. Anti-Venom Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
    Table 3. Major Players of Polyvalent Anti-Venom
    Table 4. Major Players of Monovalent Anti-Venom
    Table 5. Global Anti-Venom Sales by Type (2018-2023) & (K Vials)
    Table 6. Global Anti-Venom Sales Market Share by Type (2018-2023)
    Table 7. Global Anti-Venom Revenue by Type (2018-2023) & ($ million)
    Table 8. Global Anti-Venom Revenue Market Share by Type (2018-2023)
    Table 9. Global Anti-Venom Sale Price by Type (2018-2023) & (USD/Vial)
    Table 10. Global Anti-Venom Sales by Application (2018-2023) & (K Vials)
    Table 11. Global Anti-Venom Sales Market Share by Application (2018-2023)
    Table 12. Global Anti-Venom Revenue by Application (2018-2023)
    Table 13. Global Anti-Venom Revenue Market Share by Application (2018-2023)
    Table 14. Global Anti-Venom Sale Price by Application (2018-2023) & (USD/Vial)
    Table 15. Global Anti-Venom Sales by Company (2018-2023) & (K Vials)
    Table 16. Global Anti-Venom Sales Market Share by Company (2018-2023)
    Table 17. Global Anti-Venom Revenue by Company (2018-2023) ($ Millions)
    Table 18. Global Anti-Venom Revenue Market Share by Company (2018-2023)
    Table 19. Global Anti-Venom Sale Price by Company (2018-2023) & (USD/Vial)
    Table 20. Key Manufacturers Anti-Venom Producing Area Distribution and Sales Area
    Table 21. Players Anti-Venom Products Offered
    Table 22. Anti-Venom Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    Table 23. New Products and Potential Entrants
    Table 24. Mergers & Acquisitions, Expansion
    Table 25. Global Anti-Venom Sales by Geographic Region (2018-2023) & (K Vials)
    Table 26. Global Anti-Venom Sales Market Share Geographic Region (2018-2023)
    Table 27. Global Anti-Venom Revenue by Geographic Region (2018-2023) & ($ millions)
    Table 28. Global Anti-Venom Revenue Market Share by Geographic Region (2018-2023)
    Table 29. Global Anti-Venom Sales by Country/Region (2018-2023) & (K Vials)
    Table 30. Global Anti-Venom Sales Market Share by Country/Region (2018-2023)
    Table 31. Global Anti-Venom Revenue by Country/Region (2018-2023) & ($ millions)
    Table 32. Global Anti-Venom Revenue Market Share by Country/Region (2018-2023)
    Table 33. Americas Anti-Venom Sales by Country (2018-2023) & (K Vials)
    Table 34. Americas Anti-Venom Sales Market Share by Country (2018-2023)
    Table 35. Americas Anti-Venom Revenue by Country (2018-2023) & ($ Millions)
    Table 36. Americas Anti-Venom Revenue Market Share by Country (2018-2023)
    Table 37. Americas Anti-Venom Sales by Type (2018-2023) & (K Vials)
    Table 38. Americas Anti-Venom Sales by Application (2018-2023) & (K Vials)
    Table 39. APAC Anti-Venom Sales by Region (2018-2023) & (K Vials)
    Table 40. APAC Anti-Venom Sales Market Share by Region (2018-2023)
    Table 41. APAC Anti-Venom Revenue by Region (2018-2023) & ($ Millions)
    Table 42. APAC Anti-Venom Revenue Market Share by Region (2018-2023)
    Table 43. APAC Anti-Venom Sales by Type (2018-2023) & (K Vials)
    Table 44. APAC Anti-Venom Sales by Application (2018-2023) & (K Vials)
    Table 45. Europe Anti-Venom Sales by Country (2018-2023) & (K Vials)
    Table 46. Europe Anti-Venom Sales Market Share by Country (2018-2023)
    Table 47. Europe Anti-Venom Revenue by Country (2018-2023) & ($ Millions)
    Table 48. Europe Anti-Venom Revenue Market Share by Country (2018-2023)
    Table 49. Europe Anti-Venom Sales by Type (2018-2023) & (K Vials)
    Table 50. Europe Anti-Venom Sales by Application (2018-2023) & (K Vials)
    Table 51. Middle East & Africa Anti-Venom Sales by Country (2018-2023) & (K Vials)
    Table 52. Middle East & Africa Anti-Venom Sales Market Share by Country (2018-2023)
    Table 53. Middle East & Africa Anti-Venom Revenue by Country (2018-2023) & ($ Millions)
    Table 54. Middle East & Africa Anti-Venom Revenue Market Share by Country (2018-2023)
    Table 55. Middle East & Africa Anti-Venom Sales by Type (2018-2023) & (K Vials)
    Table 56. Middle East & Africa Anti-Venom Sales by Application (2018-2023) & (K Vials)
    Table 57. Key Market Drivers & Growth Opportunities of Anti-Venom
    Table 58. Key Market Challenges & Risks of Anti-Venom
    Table 59. Key Industry Trends of Anti-Venom
    Table 60. Anti-Venom Raw Material
    Table 61. Key Suppliers of Raw Materials
    Table 62. Anti-Venom Distributors List
    Table 63. Anti-Venom Customer List
    Table 64. Global Anti-Venom Sales Forecast by Region (2024-2029) & (K Vials)
    Table 65. Global Anti-Venom Revenue Forecast by Region (2024-2029) & ($ millions)
    Table 66. Americas Anti-Venom Sales Forecast by Country (2024-2029) & (K Vials)
    Table 67. Americas Anti-Venom Revenue Forecast by Country (2024-2029) & ($ millions)
    Table 68. APAC Anti-Venom Sales Forecast by Region (2024-2029) & (K Vials)
    Table 69. APAC Anti-Venom Revenue Forecast by Region (2024-2029) & ($ millions)
    Table 70. Europe Anti-Venom Sales Forecast by Country (2024-2029) & (K Vials)
    Table 71. Europe Anti-Venom Revenue Forecast by Country (2024-2029) & ($ millions)
    Table 72. Middle East & Africa Anti-Venom Sales Forecast by Country (2024-2029) & (K Vials)
    Table 73. Middle East & Africa Anti-Venom Revenue Forecast by Country (2024-2029) & ($ millions)
    Table 74. Global Anti-Venom Sales Forecast by Type (2024-2029) & (K Vials)
    Table 75. Global Anti-Venom Revenue Forecast by Type (2024-2029) & ($ Millions)
    Table 76. Global Anti-Venom Sales Forecast by Application (2024-2029) & (K Vials)
    Table 77. Global Anti-Venom Revenue Forecast by Application (2024-2029) & ($ Millions)
    Table 78. CSL Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 79. CSL Anti-Venom Product Portfolios and Specifications
    Table 80. CSL Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 81. CSL Main Business
    Table 82. CSL Latest Developments
    Table 83. Merck Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 84. Merck Anti-Venom Product Portfolios and Specifications
    Table 85. Merck Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 86. Merck Main Business
    Table 87. Merck Latest Developments
    Table 88. BTG Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 89. BTG Anti-Venom Product Portfolios and Specifications
    Table 90. BTG Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 91. BTG Main Business
    Table 92. BTG Latest Developments
    Table 93. Pfizer Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 94. Pfizer Anti-Venom Product Portfolios and Specifications
    Table 95. Pfizer Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 96. Pfizer Main Business
    Table 97. Pfizer Latest Developments
    Table 98. Haffkine Bio-Pharmaceutical Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 99. Haffkine Bio-Pharmaceutical Anti-Venom Product Portfolios and Specifications
    Table 100. Haffkine Bio-Pharmaceutical Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 101. Haffkine Bio-Pharmaceutical Main Business
    Table 102. Haffkine Bio-Pharmaceutical Latest Developments
    Table 103. Rare Disease Therapeutics Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 104. Rare Disease Therapeutics Anti-Venom Product Portfolios and Specifications
    Table 105. Rare Disease Therapeutics Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 106. Rare Disease Therapeutics Main Business
    Table 107. Rare Disease Therapeutics Latest Developments
    Table 108. Flynn Pharma Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 109. Flynn Pharma Anti-Venom Product Portfolios and Specifications
    Table 110. Flynn Pharma Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 111. Flynn Pharma Main Business
    Table 112. Flynn Pharma Latest Developments
    Table 113. Vins Bioproducts Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 114. Vins Bioproducts Anti-Venom Product Portfolios and Specifications
    Table 115. Vins Bioproducts Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 116. Vins Bioproducts Main Business
    Table 117. Vins Bioproducts Latest Developments
    Table 118. Bharat Serums and Vaccines Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 119. Bharat Serums and Vaccines Anti-Venom Product Portfolios and Specifications
    Table 120. Bharat Serums and Vaccines Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 121. Bharat Serums and Vaccines Main Business
    Table 122. Bharat Serums and Vaccines Latest Developments
    Table 123. Serum Biotech Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 124. Serum Biotech Anti-Venom Product Portfolios and Specifications
    Table 125. Serum Biotech Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 126. Serum Biotech Main Business
    Table 127. Serum Biotech Latest Developments
    Table 128. MicroPharm Basic Information, Anti-Venom Manufacturing Base, Sales Area and Its Competitors
    Table 129. MicroPharm Anti-Venom Product Portfolios and Specifications
    Table 130. MicroPharm Anti-Venom Sales (K Vials), Revenue ($ Million), Price (USD/Vial) and Gross Margin (2018-2023)
    Table 131. MicroPharm Main Business
    Table 132. MicroPharm Latest Developments
List of Figures
    Figure 1. Picture of Anti-Venom
    Figure 2. Anti-Venom Report Years Considered
    Figure 3. Research Objectives
    Figure 4. Research Methodology
    Figure 5. Research Process and Data Source
    Figure 6. Global Anti-Venom Sales Growth Rate 2018-2029 (K Vials)
    Figure 7. Global Anti-Venom Revenue Growth Rate 2018-2029 ($ Millions)
    Figure 8. Anti-Venom Sales by Region (2018, 2022 & 2029) & ($ Millions)
    Figure 9. Product Picture of Polyvalent Anti-Venom
    Figure 10. Product Picture of Monovalent Anti-Venom
    Figure 11. Global Anti-Venom Sales Market Share by Type in 2022
    Figure 12. Global Anti-Venom Revenue Market Share by Type (2018-2023)
    Figure 13. Anti-Venom Consumed in Non-profit Institutions
    Figure 14. Global Anti-Venom Market: Non-profit Institutions (2018-2023) & (K Vials)
    Figure 15. Anti-Venom Consumed in Hospitals and Clinic
    Figure 16. Global Anti-Venom Market: Hospitals and Clinic (2018-2023) & (K Vials)
    Figure 17. Global Anti-Venom Sales Market Share by Application (2022)
    Figure 18. Global Anti-Venom Revenue Market Share by Application in 2022
    Figure 19. Anti-Venom Sales Market by Company in 2022 (K Vials)
    Figure 20. Global Anti-Venom Sales Market Share by Company in 2022
    Figure 21. Anti-Venom Revenue Market by Company in 2022 ($ Million)
    Figure 22. Global Anti-Venom Revenue Market Share by Company in 2022
    Figure 23. Global Anti-Venom Sales Market Share by Geographic Region (2018-2023)
    Figure 24. Global Anti-Venom Revenue Market Share by Geographic Region in 2022
    Figure 25. Americas Anti-Venom Sales 2018-2023 (K Vials)
    Figure 26. Americas Anti-Venom Revenue 2018-2023 ($ Millions)
    Figure 27. APAC Anti-Venom Sales 2018-2023 (K Vials)
    Figure 28. APAC Anti-Venom Revenue 2018-2023 ($ Millions)
    Figure 29. Europe Anti-Venom Sales 2018-2023 (K Vials)
    Figure 30. Europe Anti-Venom Revenue 2018-2023 ($ Millions)
    Figure 31. Middle East & Africa Anti-Venom Sales 2018-2023 (K Vials)
    Figure 32. Middle East & Africa Anti-Venom Revenue 2018-2023 ($ Millions)
    Figure 33. Americas Anti-Venom Sales Market Share by Country in 2022
    Figure 34. Americas Anti-Venom Revenue Market Share by Country in 2022
    Figure 35. Americas Anti-Venom Sales Market Share by Type (2018-2023)
    Figure 36. Americas Anti-Venom Sales Market Share by Application (2018-2023)
    Figure 37. United States Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 38. Canada Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 39. Mexico Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 40. Brazil Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 41. APAC Anti-Venom Sales Market Share by Region in 2022
    Figure 42. APAC Anti-Venom Revenue Market Share by Regions in 2022
    Figure 43. APAC Anti-Venom Sales Market Share by Type (2018-2023)
    Figure 44. APAC Anti-Venom Sales Market Share by Application (2018-2023)
    Figure 45. China Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 46. Japan Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 47. South Korea Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 48. Southeast Asia Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 49. India Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 50. Australia Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 51. China Taiwan Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 52. Europe Anti-Venom Sales Market Share by Country in 2022
    Figure 53. Europe Anti-Venom Revenue Market Share by Country in 2022
    Figure 54. Europe Anti-Venom Sales Market Share by Type (2018-2023)
    Figure 55. Europe Anti-Venom Sales Market Share by Application (2018-2023)
    Figure 56. Germany Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 57. France Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 58. UK Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 59. Italy Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 60. Russia Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 61. Middle East & Africa Anti-Venom Sales Market Share by Country in 2022
    Figure 62. Middle East & Africa Anti-Venom Revenue Market Share by Country in 2022
    Figure 63. Middle East & Africa Anti-Venom Sales Market Share by Type (2018-2023)
    Figure 64. Middle East & Africa Anti-Venom Sales Market Share by Application (2018-2023)
    Figure 65. Egypt Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 66. South Africa Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 67. Israel Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 68. Turkey Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 69. GCC Country Anti-Venom Revenue Growth 2018-2023 ($ Millions)
    Figure 70. Manufacturing Cost Structure Analysis of Anti-Venom in 2022
    Figure 71. Manufacturing Process Analysis of Anti-Venom
    Figure 72. Industry Chain Structure of Anti-Venom
    Figure 73. Channels of Distribution
    Figure 74. Global Anti-Venom Sales Market Forecast by Region (2024-2029)
    Figure 75. Global Anti-Venom Revenue Market Share Forecast by Region (2024-2029)
    Figure 76. Global Anti-Venom Sales Market Share Forecast by Type (2024-2029)
    Figure 77. Global Anti-Venom Revenue Market Share Forecast by Type (2024-2029)
    Figure 78. Global Anti-Venom Sales Market Share Forecast by Application (2024-2029)
    Figure 79. Global Anti-Venom Revenue Market Share Forecast by Application (2024-2029)

CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

• Primary Source
  Players/Suppliers
  Industry Experts
  Distributors/Traders
  Opinion Leaders
  Front-line Staff
  Marketing Executives

  Secondary Source
  Journals and Periodicals
  Government Bodies
  Annual Reports
  Presentations
  Paid Databases
  LPI Internal Repository

• Data Synthesis
  Information Gathering
  Collation of Data
  Estimation of Key Figures
  Analysis of Derived Insights

  Data Validation
  Triangulation with Data Models
  Reference Against Proprietary
  Databases
  Corroboration with Industry Experts

• Qualitative Analysis
  Market drivers
  Market challenges
  Market trends
  Five forces analysis

  Qualitative Analysis
  Market size and forecast
  Market segmentation
  Geographical insights
  Competitive landscape